274 related articles for article (PubMed ID: 11922402)
1. Pure antiestrogens and breast cancer.
Elkak AE; Mokbel K
Curr Med Res Opin; 2001; 17(4):282-9. PubMed ID: 11922402
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
4. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
Howell A; Osborne CK; Morris C; Wakeling AE
Cancer; 2000 Aug; 89(4):817-25. PubMed ID: 10951345
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
Bundred N; Howell A
Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
[TBL] [Abstract][Full Text] [Related]
8. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience with pure antiestrogens.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
[TBL] [Abstract][Full Text] [Related]
10. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Schafer JI; Liu H; Tonetti DA; Jordan VC
Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
[TBL] [Abstract][Full Text] [Related]
11. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Journé F; Body JJ; Leclercq G; Laurent G
Expert Opin Drug Saf; 2008 May; 7(3):241-58. PubMed ID: 18462183
[TBL] [Abstract][Full Text] [Related]
14. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
15. [Fulvestrant: a new agent in endocrine treatment for breast cancer].
Juretić A; Sarić N; Bisof V; Basić-Koretić M
Lijec Vjesn; 2006; 128(1-2):31-6. PubMed ID: 16640225
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
[TBL] [Abstract][Full Text] [Related]
17. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
Nicholson RI; Gee JM; Manning DL; Wakeling AE; Montano MM; Katzenellenbogen BS
Ann N Y Acad Sci; 1995 Jun; 761():148-63. PubMed ID: 7625718
[No Abstract] [Full Text] [Related]
18. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068).
Hermenegildo C; García-Martínez MC; Tarín JJ; Cano A
Menopause; 2002; 9(6):430-5. PubMed ID: 12439102
[TBL] [Abstract][Full Text] [Related]
20. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
